Treating Chronic Pain with Buprenorphine

Please go to V 4.0

If you do not have an account: This page is part of a larger Buprenorphine training activity provided by Clinical Tools, Inc. Our DATA 2000/CARA-qualifying Buprenorphine training provides the current information for physicians, nurse practitioners, and physician assistants on prescribing buprenorphine as an office-based treatment for opioid use disorder. Please refer to the homepage to sign-up and begin the activity!

Current accounts: If you see this message, the system has logged you out because of inactivity. To resume:

  1. Log In
  2. Go To Activity Homepage (Module list page)
  3. Re-Enter Module To Resume Training
Chronic Pain

Chronic Pain

Pain -- both acute and chronic -- is an issue that affects a large number of the patients seen within primary care settings. Given the prevalence and the cost of pain to individuals, physicians who prescribe buprenorphine may find that they are approached by patients for its use in pain management.

A 7-day buprenorphine transdermal patch (BuTrans®) has been approved by the FDA for use in treatment of long term, moderate-to-severe chronic pain (Waknine 2010). Patches are available in 5, 10, and 20 μg/hour strengths (FDA 2010). Its use is contraindicated in the management of acute or short-term, postoperative, mild, and intermittent pain. It is not approved for treatment of opioid use disorder(Purdue Pharma 2010). Note that physicians do not need their DATA 2000 waiver in order to prescribe buprenorphine for pain.

Use of sublingual buprenorphine to treat pain is considered off-label. However, if a patient is already on buprenorphine for opioid treatment, dividing the buprenorphine dose can help address pain to some extent. Keep in mind that its analgesic property is around 8 hours.

View ReferencesHide References
Edlund MJ, Martin BC, Russo JE, et al.. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014; 30(7): 557-64. Available at: Accessed on: 2014-10-07.
FDA. Medication Guide: Butrans™ CIII (buprenorphine) Transdermal System. Food and Drug Administration (FDA). 2010. Available at:
Purdue Pharma. Butrans™ CIII (buprenorphine) Transdermal System. Butrans Website. 2010. Available at:
Waknine Y. FDA Approves 7-Day Buprenorphine Pain Patch. Medscape Today. 2010. Available at: Accessed on: 2011-07-13.